EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, today announced that Jay Birnbaum, Ph.D., has joined the Company’s Scientific Advisory Board, increasing the Board to four members.
